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Dr Steven W. Guyton, MD (Portland, Ore). We don’t know if
anticoagulation is beneficial in this group of patients, but we, as you
noted, have seen that it doesn’t cause dramatic increases in bleeding
perioperatively. You noted the lack of appropriately powered ran-
domized trials of postoperative anticoagulation. This again is a ret-
rospective study and limited by selection bias, treatment bias, and
confounding. There seems to be some confusion in the article in
that you note that this confounding cannot be completely eradi-
cated, but in the next sentence you say ‘‘we have eliminated con-
founders by further restrictions on the data.’’ You tried to
decrease the bias of this retrospective study by a propensity-based
analysis, but one of your strongest conclusions is that 19-mm
valves are at higher risk, yet in your propensity analysis all the
19-mm valves dropped out. Can you try to explain that?
Dr Elbardissi. I’m not sure I understand your question, can you
please rephrase it?
Dr Guyton. When I looked at your propensity analysis data
sheet, the range of valve size was from 21 to 25 mm. All the 19-
mm valves were gone.
Dr Elbardissi. You are looking at the interquartile range. The
25th percentile was the 21-mm valve, and the 75th percentile was
the 25-mm valve.
Dr Guyton. I see, so it was not a range. It’s an interquartile. All
right. That was not clear from the data. Now your institutional prac-
tice during this study seems to have been determined by individual
surgeons. Is that correct?
Dr Elbardissi. That is correct.
Dr Guyton. And yet you note that the majority do not anticoa-
gulate with low-molecular-weight heparin, VKAs, or provide anti-
platelet therapy, but 54% of your anticoagulation-negative patients
were discharged on aspirin. It seems to me that more than half of
them had anticoagulation or aspirin.
Dr Elbardissi. That’s true. With regard to VKAs (warfarin spe-
cifically in this case), the majority of surgeons at our institution will
not anticoagulate. As you saw from my first table, there are certain
preoperative characteristics that would incline one to do so, primar-
ily in patients who are thought to be at a relatively high risk of TE.
The inclination not to provide some form of antiplatelet therapy is
less pronounced. You are correct that approximately one half of the
cohort was given aspirin, which is consistent with a more liberal
practice pattern that we observed at our institution.
Dr Guyton. Some of the conclusive statements in the article are
hidden in the body of the article where you say that VKAs or aspirin
is not indicated for widespread use in BPAV implantation and
widespread early anticoagulation offers minimal benefit. More
than half of both of your categories of anticoagulation negative/an-
ticoagulation positive were on aspirin and your final conclusion
says postoperative antithrombotic therapy should be considered
for female patients, patients with small aortic prostheses, and pa-
tients who are severely symptomatic preoperatively. It is a little un-
clear whether you are recommending anticoagulation or
antithrombotic therapy.
Dr Elbardissi. The objective of our study was not to assess the
best type of antithrombotic therapy (aspirin vs warfarin). That be-
ing said, it would have been easy to end our analysis by looking
at the thromboembolic risk with regard to anticoagulation or anti-
platelet therapy. We took it one step further, identified risk factorsgery c May 2010
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Dof TE, and then identified if providing some form of therapy was
efficacious. Because our study was not designed to assess whether
antiplatelet therapy or anticoagulation is more beneficial than the
other, we leave it open to the readers to make that assertion on
the basis of their interpretation of our data.
Dr Guyton. I agree with that. I think the important thing is that
you potentially identified areas that require additional randomized
trials to try and evaluate them.
Dr Thoralf Sundt, MD (Rochester, Minn). Drew, that was
beautifully presented. For those in the audience who do not
know, Drew was a Mayo medical student, and so we will proudly
take credit for all of his subsequent success throughout his career. I
appreciate you quoting me in your presentation because I intend to
quote you later on this morning.
Can you give us an idea about what you think the mechanism is
for this effect, the reduction in thromboembolic events, specifically
in this subset of patients. I have my own thoughts, but I would be
interested in yours first.
Dr Elbardissi.With regard to forming clot, the theory is that clot
forms on the prosthetic sewing ring. As such, youwant to anticoagu-
late or provide some form of antithrombotic therapy until endotheli-
alization of the sewing ring occurs. That being said, why are we
finding that certain subsets of patients have a higher risk of TE com-
paredwith the remainder of our cohort? I think this has to dowith the
small size of the valve and depressed left ventricular function. First,
it is important to note that we only identified univariate predictors of
TE,meaning that each predictor is not necessarily causally related to
TE andmay in fact demonstrate variability in the dataset thatwe can-
not further characterize. According to my own rigorous analysis of
the data and knowing how each of these predictors function, it is
my theory that it comes down to the 19-mm valve and depressed
left ventricular function. Why? We know from my previous labora-
tory studies that high laminar flow and decreased ejection fraction
can both contribute to the incidence of thrombus formation.
Dr Sundt. I will give you an alternative hypothesis for what it’s
worth. I’ll bet you a Coke in a bottle that what this really is a matter
of silent postoperative atrial fibrillation. I think the markers you
have looked at are markers of postoperative atrial fibrillation, and
I’ll bet it has nothing to do at all with endothelialization of the sew-
ing ring of the valve. It is just postoperative atrial fibrillation, and
the people who are at high risk for that, most of which is unrecog-
nized, are those with silent atrial fibrillation, and those who are anti-
coagulated are protected. Of course I have no proof of that, but you
might look at your left atrial size in your cohort or something likeThe Journal of Thoracic and Carthat as another predictor of atrial fibrillation. That is another thing to
consider.
Dr Craig Baker, MD (Los Angeles, Calif). At our institution,
we do not routinely anticoagulate bioprosthetic valves; we have
seen 2 cases in the last couple years of very early bioprosthetic
valve deterioration. It is difficult to describe, but it presents as ag-
gressive calcium and platelet deposits. Dr Damiano’s group de-
scribed a similar phenomena a couple of years ago in 4 patients. I
contacted him, and it is their practice not to anticoagulate patients
either. I am curious in your extensive review of all your patients,
did you have this phenomenon in your approximately 1000 pa-
tients? If you did, did you see it in anticoagulated or unanticoagu-
lated patients?
Dr Elbardissi. That is not something that we initially looked for
when reviewing these patients. It was not a hypothesis that I knew
existed with regard to the causes of TE in this cohort of patients, but
it is something interesting that we can certainly look at.
DrNimesh Desai, MD (Philadelphia, Pa). One quick comment
about the 19-mm valve hypothesis. In our experience, and this is
borne out in the literature, patients who receive 19-mm valves are
just a different group of patients. They are older. They are female.
They are sick. They have severe atherosclerosis. Their valves are
tremendously calcified. Their roots are calcified. Their ascending
aortas have calcium in them, as do their arches. Although there is
certainly a scientific hypothesis that a smaller valve that has dif-
ferent flow characteristics may be more thrombogenic, these pa-
tients are at risk for stroke for any cardiac operation and are
actually at elevated risk for stroke even if they didn’t have heart
surgery.
Dr Elbardissi. I appreciate that comment. If we only looked at
the predictors of TE, I agree that it would be hard to endorse pro-
viding some form of antithrombotic therapy. However, we had
enough variability in our practice patterns to evaluate whether ei-
ther form of antithrombotic therapy was efficacious in this group.
In fact, we saw a reduction in the incidence of TE in patients
with 19-mm valves. This indicates that regardless of the cause,
we should at least be aware of the potential risk reduction that exists
with antithrombotic therapy when implanting these valves and be
aggressive by providing at least aspirin postoperatively.
Dr Desai. In your model did you correct for the presence of pe-
ripheral vascular disease or cerebrovascular disease?
Dr Elbardissi. Yes. Initially, anticoagulated patients had
a higher incidence of peripheral vascular disease. After propensity
adjustment, that was no longer significant.diovascular Surgery c Volume 139, Number 5 1145
